MannKind opens up partnership talks

MannKind told analysts yesterday afternoon that it has opened up discussions with a few more potential commercial partners for Afrezza, an inhaled insulin product that is waiting on a final ruling from the FDA. The agency delayed its decision on the fast-acting insulin--which has attracted a big crowd of skeptics and true believers--in the middle of January, saying that it had not completed an inspection of a third-party manufacturing site. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.